All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Acclaim-1 Trial of Quaratusugene Ozeplasmid Plus Osimertinib in NSCLC Advances Into Phase 2 Expansion

May 30th 2023

The safety review committee for the phase 1/2 Acclaim-1 trial has ruled that the study evaluating quaratusugene ozeplasmid in combination with osimertinib in patients with advanced non–small cell lung cancer can proceed to the phase 2 expansion portion.

Improvements in Personalized Medicine Allow for Greater Exploration of Treatment De-escalation in Breast Cancer

May 30th 2023

Suzanne B. Coopey, MD, FACS, discusses the de-escalation of axillary lymph node surgery, shifts in the use of radiation oncology, and changes in the treatment paradigm for HER2-positive breast cancer.

STAT2 Expression Is Higher in African American, Asian Patients With HCC

May 30th 2023

STAT2 expression in patients with hepatocellular carcinoma increases with tumor grade and cancer stage, with increases occurring at greater rates among Asian and African American patients.

Breast, Rectal, Kidney and Brain Cancer Phase 3 Trials Headline Dana-Farber Research at ASCO Annual Meeting

May 30th 2023

Several phase 3 studies conducted by researchers from Dana-Farber Cancer Institute show promising results for patients with rectal, brain, and kidney cancers.

FDA Grants Priority Review to Lifileucel in Advanced Melanoma

May 30th 2023

The FDA has granted priority review to the biologics license application for the tumor infiltrating lymphocyte therapy lifileucel for the treatment of patients with advanced melanoma who progressed on or after prior anti–PD-1/PD-L1 therapy and targeted therapy.

FDA Grants Priority Review to Repotrectinib for ROS1+ NSCLC

May 30th 2023

The FDA has granted priority review to repotrectinib for the treatment of patients with ROS1-positive locally advanced or metastatic non–small cell lung cancer.

Colocation Approach Leads to Decreased Time to Diagnosis, Stimulates Clinician Collaboration

May 30th 2023

Investigators at Dana-Farber Cancer Institute in Boston, Massachusetts, developed a clinical outreach program combining diagnostic and patient navigation services.

FDA Approves First Radiohybrid PSMA-targeted PET Imaging Agent for Prostate Cancer

May 30th 2023

The FDA has approved flotufolastat F 18 injection (Posluma) for positron emission tomography of prostate-specific membrane antigen–positive lesions in men with prostate cancer with suspected metastasis who are eligible for initial definitive therapy or with suspected recurrence based on elevated serum prostate-specific antigen level.

Strong Link Between Bone Biomarkers and Prostate Cancer Survival

May 29th 2023

New study led by UC Davis Comprehensive Cancer Center could improve outcomes for common cancer found in 1 in 8 men.

Shifts In Ovarian Cancer Treatment Options Necessitate Continued Research

May 29th 2023

Whitfield B. Growdon, MD, discusses the role PARP inhibitors have played in ovarian cancer since their introduction to the field, the updated clinical trial data that contributed to the indication withdrawals for these agents, and where future research in this area may be headed.

GCC’s Pharmacogenomics Program May Help Reduce Side Effects from Chemotherapy for Some Patients

May 29th 2023

The Georgia Cancer Center Pharmacogenomics Program has launched its pharmacogenomics testing services for Georgia Cancer Center patients and oncologists.

Latinx Patients Highlight Barriers to Tumor Genomic Profiling for Cancer

May 29th 2023

Latinx patients with cancer had a low rate of tumor genomic profiling, partially due to structural and cultural barriers, according to findings from a qualitative study presented during the 5th Annual Regional SPEECH Conference and Retreat.

Efforts to Explore Current Therapeutics in Earlier Treatment Lines Continue Across Breast Cancer Subtypes

May 28th 2023

Christie J. Hilton, DO, details the evolving role of trastuzumab deruxtecan in HER2-positive breast cancer and the potential to de-escalate therapy in early-stage disease.

Venetoclax Plus Obinutuzumab With or Without Ibrutinib Improves Undetectable MRD Rates in Fit Patients With CLL

May 27th 2023

The combination of venetoclax and obinutuzumab with or without ibrutinib generated higher rates of undetectable minimal residual disease (MRD) and progression-free survival vs chemoimmunotherapy in fit patients with chronic lymphocytic leukemia.

Improving Durability of Responses Is a Key Next Step for CAR T-cell Therapy in Myeloma

May 26th 2023

Susan Bal, MD, discusses the data that supported the FDA approvals of ide-cel and cilta-cel, how the implementation of these agents has shifted how patients with later-line relapsed/refractory multiple myeloma are treated, and the challenges that still need to be addressed with CAR T-cell therapy.

Liver Cancer Awareness Higher in Individuals Who Receive HBV/HCV Screening

May 26th 2023

Individuals in Philadelphia and New York City who were screened for the common liver cancer risk factors hepatitis B virus or hepatitis C virus displayed a higher level of knowledge of liver cancer.

BET Inhibition Highlights Exploration of Novel Targeted Approaches in Myelofibrosis

May 26th 2023

Andrew T. Kuykendall, MD, expands on the rationale for exploring BET inhibition in the treatment of patients with myelofibrosis, details the implications of data from the MANIFEST trial, and discusses other potential targets for novel therapies for myelofibrosis.

European Approval Sought for Cilta-cel in Relapsed and Lenalidomide-Refractory Myeloma

May 26th 2023

A Type II variation application seeking the approval of ciltacabtagene autoleucel in adult patients with relapsed and lenalidomide-refractory multiple myeloma has been submitted to the European Medicines Agency.

EMA Recommends Approval of Neoadjuvant Nivolumab/Chemotherapy in Resectable NSCLC

May 26th 2023

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the approval of nivolumab as neoadjuvant therapy in combination with platinum-based chemotherapy for patients with resectable non–small cell lung cancer at high risk of recurrence and tumor cell PD-L1 expression of at least 1%.

Durvalumab Plus Chemotherapy With or Without Olaparib Improves PFS in Advanced Endometrial Cancer

May 26th 2023

The combination of durvalumab and platinum-based chemotherapy, followed by maintenance therapy with either durvalumab plus olaparib or durvalumab alone, elicited a statistically significant and clinically meaningful improvement in progression-free survival in patients with newly diagnosed, advanced or recurrent endometrial cancer.